Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) cause a significantly higher rate of intolerable gastrointestinal adverse reactions leading to drug withdrawal compared to other hypoglycemic agents (Insulin, SGLT2i, DPP4i, TZD) and placebo.

If you are considering a GLP-1RA, expect a higher likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea) compared to other common diabetes drugs like Metformin or SGLT2 inhibitors. These side effects are the most common reason for stopping the medication. However, not all GLP-1RAs carry the same risk; Dulaglutide appears to have the lowest risk of intolerable GI reactions, while Semaglutide and Liraglutide have higher risks, especially at higher doses.

Leptin analogs (metreleptin) are effective for treating obesity only in patients with generalized lipodystrophy or congenital leptin deficiency, but are ineffective and contraindicated for general diet-based obesity due to leptin resistance.

Leptin analogs like metreleptin are not for general weight loss. They are reserved for rare genetic conditions like generalized lipodystrophy where the body cannot produce leptin. For most people with obesity, leptin levels are already high, and adding more does not help.

MC4R agonists (setmelanotide) are effective for treating obesity in individuals with specific genetic deficiencies (POMC, PCSK1, LEPR) or Bardet-Biedl syndrome, but are not approved for general obesity.

If you have a rare genetic condition like POMC deficiency or Bardet-Biedl syndrome, ask your doctor about setmelanotide. It is a daily injection approved for these specific conditions. It is not approved for general obesity.

The association between ultra-processed food consumption and colorectal cancer risk is significant in men but not in women, and there is no significant association with prostate, rectal, pancreatic, or central nervous system cancers.

If you are male, be particularly mindful of UPF intake as it is linked to a higher risk of colorectal cancer. For women, the link to colorectal cancer was not statistically significant in this study. There was no significant link found for prostate, rectal, pancreatic, or brain cancers.

In individuals with type 2 diabetes and obesity, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) does not increase the risk of suicidal ideation or self-injury (SIS) compared to sodium-glucose cotransporter 2 inhibitors (SGLT-2i).

If you have type 2 diabetes and obesity, current evidence suggests that GLP-1RA medications do not increase your risk of suicidal thoughts or self-harm compared to other common diabetes drugs like SGLT-2 inhibitors. While regulators are reviewing safety data based on early reports, this large study found no such link. However, because these events are rare, the possibility of a small increased risk cannot be completely excluded, so monitoring your mental health remains important.

High-dose GLP-1 receptor agonists and treatment of patients with higher baseline BMI are associated with a significantly increased risk of ventricular arrhythmias (VAs).

If you are taking a high dose of a GLP-1 medication (like the maximum weight-loss doses of Ozempic or Saxenda), especially if you have a higher body weight, there is a slightly increased risk of ventricular arrhythmias. Doctors should monitor these patients more closely. However, this risk is specific to high doses and higher BMI, not the standard doses used for diabetes.

Oral semaglutide is associated with a significantly lower risk of incident atrial fibrillation (AF), while dulaglutide shows an increasing trend toward higher AF risk compared to controls.

Among GLP-1 medications, oral semaglutide (Rybelsus) may actually lower the risk of atrial fibrillation, while dulaglutide (Trulicity) might slightly increase it. This difference is drug-specific and not seen with all GLP-1s. If you have a history of AF, discuss the specific drug choice with your doctor.

GLP-1 receptor agonists (GLP-1 RAs) significantly increase the risk of gastrointestinal adverse events, specifically intestinal obstruction and perioperative aspiration, due to delayed gastric emptying.

If you are taking a GLP-1 medication (like Ozempic or Wegovy) and have surgery or an endoscopy, tell your medical team. You may need to adjust your fasting time or pause the medication to prevent stomach contents from entering your lungs, which is a known risk of these drugs.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly with weight-loss focused dosing and specific agents like liraglutide.

Be aware that GLP-1 medications can increase the risk of gallstones, especially if you are losing weight rapidly. Report any abdominal pain to your doctor. This risk is higher with weight-loss doses compared to diabetes doses.

Current evidence does not support a significant increased risk of acute pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists in human populations, despite early animal studies and spontaneous reports.

You do not need to worry about developing pancreatitis or pancreatic cancer from GLP-1 medications. Large studies have confirmed they are safe in this regard, although you should stop the medication if you experience severe abdominal pain.

An acute high-fat diet increases the activity of AMPK and SIRT1 in skeletal muscle (via phosphorylation and deacetylation, respectively) without changing the total protein or mRNA levels of these enzymes.

Your body can rapidly switch on fat-burning enzymes in your muscles just by changing what you eat, even if the total amount of those enzymes doesn't change. This happens through chemical tags (phosphorylation/deacetylation) that activate the enzymes. This is a fast-acting regulatory mechanism, not a slow structural change.

Beta cell reserve and function are critical determinants of whether type 2 diabetes remission can be achieved and sustained, regardless of the amount of weight loss.

Even if you lose weight, your body's ability to produce insulin (beta cell function) determines if your diabetes goes into remission. This is why early intervention is crucial. If you have had diabetes for a long time, your beta cells may be too damaged to recover, even with significant weight loss.

Low-intensity endurance exercise with blood flow restriction (BFR-EE) fails to upregulate PGC-1α isoforms to the extent of moderate-intensity endurance exercise, suggesting it provides an insufficient stimulus for mitochondrial biogenesis signaling.

If your goal is improving mitochondrial density or VO2 max, low-intensity cycling with blood flow restriction is not a sufficient substitute for moderate-intensity endurance training. While BFR may help with muscle strength or size at low loads, it does not trigger the same molecular signals (PGC-1α) as standard endurance exercise.

Women with PCOS exhibit significantly higher basal levels of circulating miRNA-27b compared to BMI-matched healthy controls, independent of adipose tissue expression levels.

Women with PCOS have distinct molecular markers in their blood (specifically miRNA-27b) compared to healthy women of the same weight. This suggests PCOS involves specific metabolic dysregulation that is not solely explained by body fat levels.

Women experience a higher incidence of gastrointestinal adverse events (nausea, vomiting) from GLP-1 receptor agonists compared to men, even at similar drug exposure levels.

Women are more likely to experience nausea and vomiting from GLP-1 drugs than men. This is a known side effect. Use the recommended slow titration schedule to minimize these symptoms.

Tirzepatide 10mg and 15mg doses are associated with significantly higher rates of discontinuation due to adverse events compared to GLP-1 receptor agonists, primarily driven by gastrointestinal adverse events.

If you are using Tirzepatide at 10mg or 15mg, be aware that you are more likely to stop the medication due to side effects (like nausea or diarrhea) compared to using other GLP-1 drugs like semaglutide or dulaglutide. This risk is dose-dependent. If side effects become intolerable, discuss dose reduction or switching with your provider.

Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.

If you are taking a GLP-1 RA (like semaglutide or liraglutide), your common genetic risk for obesity does not predict how much weight you will lose. The drug's effectiveness is largely independent of your polygenic score for BMI or Type 2 Diabetes. Focus on adherence and lifestyle factors rather than genetic testing for treatment selection.

GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.

If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.

Metformin exerts glucose-lowering effects partly by altering gut microbiota composition to increase the production of short-chain fatty acids (propionate and butyrate) and modulate bile acid pools, which in turn stimulate incretin hormone release.

If you take metformin, part of its benefit comes from how it changes your gut bacteria to produce beneficial compounds like butyrate. Some people experience stomach upset or gas initially, which is a known side effect linked to these microbial changes. This discomfort often improves over time.

FXR agonists (e.g., obeticholic acid) improve MASH histology but are limited by side effects like pruritus and increased LDL cholesterol.

FXR agonists like obeticholic acid can improve liver scarring and inflammation in MASH. However, they often cause severe itching and can raise bad cholesterol (LDL). They are not first-line treatments and require careful monitoring for side effects.

Obesity induces a state of CD4 T-cell exhaustion and senescence in visceral adipose tissue (VAT), characterized by persistent PD-1 expression and restricted effector function, which creates a negative legacy that persists after weight loss and contributes to treatment resistance.

If you have a history of obesity, simply losing weight may not fully reset your immune system's behavior in fat tissue. This 'immune memory' can make you more prone to inflammation and weight regain. Strategies to manage this might focus on long-term immune health and reducing chronic inflammation, rather than just short-term weight loss, as the immune system in visceral fat may remain 'exhausted' or 'senescent' even at a lower weight.

Leptin acts as a key initiator of VAT inflammation by promoting the differentiation of CD4 T cells into Th1 and Th17 subsets and inducing T-cell exhaustion via STAT3 signaling and PD-1 expression.

High levels of leptin in obesity don't just signal hunger; they actively reprogram immune cells in fat tissue to become pro-inflammatory and exhausted. This suggests that managing leptin sensitivity or levels might be important for reducing chronic inflammation associated with obesity.

Adiponectin normally suppresses VAT T-cell inflammation by inhibiting T-cell proliferation and promoting apoptosis, but its levels are reduced in obesity, thereby releasing the 'brake' on inflammatory T-cell responses.

Low levels of adiponectin in obesity remove a natural 'brake' on inflammation. Maintaining or boosting adiponectin (often through exercise and weight management) may help keep immune cells in fat tissue from becoming overly inflammatory.

Chronic inflammation in adipose tissue, driven by macrophage infiltration (M1 phenotype) and pro-inflammatory cytokine release (TNFα, IL-6), directly causes insulin resistance and contributes to the development of obesity and metabolic syndrome.

Obesity involves a biological feedback loop where excess fat tissue triggers chronic inflammation, which worsens insulin resistance and makes weight loss harder. Reducing fat mass is the most effective way to lower this inflammation and improve metabolic health, rather than just focusing on calorie counting alone.